• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

4.650 -0.010 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tvardi Therapeutics, Inc. - Common Stock

TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
October 31, 2025
From The Schall Law Firm
Via Business Wire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 30, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 26, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
October 24, 2025
From The Rosen Law Firm, P.A.
Via Business Wire
Unusual volume stocks in Monday's session
October 20, 2025
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
In today's session, these stocks are experiencing unusual volume.
October 16, 2025
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
Unusual volume stocks in Wednesday's session
October 15, 2025
Which stocks have an unusual volume on Wednesday? 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 14, 2025
 
Via Benzinga
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 13, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks
October 13, 2025
Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response. 
Via Benzinga
Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge
October 13, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 13, 2025
 
Via Benzinga
Dow Surges 1%; Fastenal Shares Fall After Q3 Results
October 13, 2025
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 13, 2025
 
Via Benzinga
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?
October 13, 2025
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review... 
Via Stocktwits
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
October 13, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
August 21, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Posts Q2 Net Income Turnaround
August 14, 2025
Via The Motley Fool
Topics Intellectual Property
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
August 14, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
July 15, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
June 12, 2025
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
Via Benzinga
This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
June 12, 2025
 
Via Benzinga
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 27, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 13, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
May 06, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 02, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 25, 2025
 
Via Benzinga
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
April 25, 2025
 
Via Benzinga
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap